MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

B7-H3, also known as CD276, is an immunoregulatory protein that is overexpressed in tumour tissue, notably in lung, breast, ovarian, gastric, and brain cancer, as well as squamous cell carcinoma ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.

（原标题：【券商聚焦】海通国际首予翰森制药 (03692)“优于大市”评级 指其肿瘤板块优势稳固） 金吾财讯 | 海通国际发研指，翰森制药 (03692)创新药收入由2021年的44亿元增长至2024年的95亿元，占比由45%提升至77%。该机构预计2025年创新药收入有望超100亿元，占收入比重突破80%。 该机构指，2024年肿瘤板块收入81亿元，同比+32%，占总营收比例66%。阿美替尼已有 ...

The crystal structure of B7-consists of a unique combination of two Ig domains. One is characteristic of an adhesion receptor and the other has only been seen previously in antigen receptors 25.

The White House says President Donald Trump will decide within the next two weeks whether to strike Iran. It says Trump still ...

Israel’s defense minister threatened Iran’s supreme leader after Iranian missiles damaged a hospital in southern Israel and ...

The Israeli military said Thursday that Iran used a missile with multiple warheads in its attack, posing a new challenge to ...

This evening will be dry and settled with a mix of variable cloud and clear intervals. Overnight, skies will become extensively clear. Tuesday Tomorrow will be a dry and warm day with lengthy ...